| P2093 | author name string | Masanori Ikeda | |
| | Nobuyuki Kato | |
| P2860 | cites work | Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bio | Q43031767 |
| | Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study | Q43032179 |
| | Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial | Q43047961 |
| | Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes | Q44217878 |
| | Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells | Q44743426 |
| | Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo. | Q44755021 |
| | Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease | Q45474964 |
| | Prevalence of antibody against non-A, non-B hepatitis virus in Japanese patients with hepatocellular carcinoma | Q45850898 |
| | Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus | Q46505019 |
| | Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. | Q54180777 |
| | Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report | Q70313812 |
| | Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication | Q24302046 |
| | Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity | Q24305492 |
| | Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90 | Q24306116 |
| | Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase | Q24306483 |
| | Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus | Q24336255 |
| | RNA virus error catastrophe: direct molecular test by using ribavirin | Q24599371 |
| | Pleiotropic effects of statins | Q24647863 |
| | Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation | Q27469769 |
| | Effect of alpha interferon on the hepatitis C virus replicon | Q27469963 |
| | Robust hepatitis C virus infection in vitro | Q27470013 |
| | Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs | Q27472783 |
| | Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells | Q27472846 |
| | Persistent and transient replication of full-length hepatitis C virus genomes in cell culture | Q27472869 |
| | Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons | Q27473083 |
| | Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs | Q27473092 |
| | Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells | Q27473106 |
| | Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras | Q27473179 |
| | Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication | Q27473218 |
| | VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells | Q27473228 |
| | Efficient Replication of Hepatitis C Virus Genotype 1a RNAs in Cell Culture | Q27473339 |
| | Interference of hepatitis C virus RNA replication by short interfering RNAs | Q27473349 |
| | Hepatitis C Virus RNA Replication Occurs on a Detergent-Resistant Membrane That Cofractionates with Caveolin-2 | Q27473377 |
| | NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon | Q27477455 |
| | Small Interfering RNA Targeted to Hepatitis C Virus 5' Nontranslated Region Exerts Potent Antiviral Effect | Q27478036 |
| | Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture | Q27480270 |
| | Efficient initiation of HCV RNA replication in cell culture | Q27860520 |
| | Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line | Q27860561 |
| | Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 |
| | Production of infectious hepatitis C virus in tissue culture from a cloned viral genome | Q27860899 |
| | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| | Complete replication of hepatitis C virus in cell culture | Q27860934 |
| | Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon | Q28344042 |
| | Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro | Q28360752 |
| | An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus | Q29614207 |
| | Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease | Q29614208 |
| | Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon | Q29619491 |
| | Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium | Q29619747 |
| | Mechanism of action of interferon and ribavirin in treatment of hepatitis C | Q29619805 |
| | Hepatitis C virus replication in mice with chimeric human livers | Q29620650 |
| | Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids | Q29620653 |
| | Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro | Q31146715 |
| | Mizoribine and mycophenolate mofetil | Q33676967 |
| | Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. | Q33791625 |
| | Host cell factor requirement for hepatitis C virus enzyme maturation | Q33950214 |
| | Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. | Q34167398 |
| | Recent advances in the analysis of HCV NS5B RNA-dependent RNA polymerase | Q34183101 |
| | Molecular virology of hepatitis C virus | Q34297465 |
| | The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro | Q34504825 |
| | Inhibition of dengue virus replication by mycophenolic acid and ribavirin | Q34535822 |
| | Different anti-HCV profiles of statins and their potential for combination therapy with interferon | Q34541863 |
| | Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation | Q34792600 |
| | Glycosylation of hepatitis C virus envelope proteins | Q35138103 |
| | Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. | Q35588125 |
| | A critical role for the chimpanzee model in the study of hepatitis C. | Q35797579 |
| | Antiviral therapy for chronic hepatitis C: past, present, and future | Q36406543 |
| | The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus | Q36406550 |
| | Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors | Q36960679 |
| | Identification of active antiviral compounds against a New York isolate of West Nile virus | Q38884300 |
| | Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. | Q40180818 |
| | Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice | Q40188501 |
| | Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. | Q40209090 |
| | Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. | Q40214644 |
| | In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease | Q40262817 |
| | Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model | Q40272019 |
| | S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro | Q40300400 |
| | Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. | Q40306689 |
| | Host sphingolipid biosynthesis as a target for hepatitis C virus therapy | Q40330820 |
| | Hepatitis C virus NS5B delays cell cycle progression by inducing interferon-beta via Toll-like receptor 3 signaling pathway without replicating viral genomes | Q40344166 |
| | Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins | Q40376973 |
| | Hepatitis C virus proteins exhibit conflicting effects on the interferon system in human hepatocyte cells | Q40378595 |
| | Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication | Q40436570 |
| | Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha | Q40439150 |
| | Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. | Q40447017 |
| | Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. | Q40466445 |
| | cDNA microarray analysis to compare HCV subgenomic replicon cells with their cured cells | Q40487547 |
| | Mycophenolic acid inhibits avian reovirus replication | Q40510563 |
| | The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase | Q40517134 |
| | Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype | Q40518459 |
| | Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts | Q40543432 |
| | Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha | Q40576649 |
| | Specific inhibition of hepatitis C virus replication by cyclosporin A. | Q40607971 |
| | Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes | Q40622941 |
| | Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. | Q40627485 |
| | Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro | Q40628677 |
| | The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. | Q40643235 |
| | Subgenomic replicon derived from a cell line infected with the hepatitis C virus | Q40727114 |
| | Antiviral action of ribavirin in chronic hepatitis C. | Q42983488 |
| | Anti-HCV activities of selective polyunsaturated fatty acids | Q42984636 |
| | Transmission of hepatitis C virus infection to tree shrews | Q42988176 |
| | Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-alpha | Q42988927 |
| | Genetic variation and dynamics of hepatitis C virus replicons in long-term cell culture | Q42990842 |
| | Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent. | Q42995409 |
| | Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type I interferon receptors | Q42995451 |
| | Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C. | Q42996587 |
| | Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells | Q42999017 |
| | Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. | Q42999156 |
| | Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication | Q42999797 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1277-1289 | |
| P577 | publication date | 2007-08-11 | |
| P1433 | published in | Advanced Drug Delivery Reviews | Q2825362 |
| P1476 | title | Modulation of host metabolism as a target of new antivirals | |
| P478 | volume | 59 | |